Clinical trials

The following list shows the clinical trials currently open at the two sarcoma centres in London and the South East: University College London (UCLH) and The Royal Marsden (RMH). For further information please contact the research nurses at each site:

Last updated April 2023

Name Description Type Centre Age
Afatinib A phase II, single arm, multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in metastatic or unresectable chordoma Phase II UCLH ≥18 years
BI 1403-0002 Phase Ib part will be performed in patients with TP53 wt advanced and/or metastatic, soft tissue sarcomas Phase Ib RMH
BI 1403-0008 A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma Phase II/III RMH
EHE Biobank UK Biobank for epithelioid haemangioendothelioma RMH
EHE Study Milan Evaluation of cytokines and hormonal profile as biomarker in epithelioid haemangioendothelioma RMH
EMPRASS Elucidation of a molecular signature of pazopanib response in advanced soft tissue sarcoma including solitary fibrous tumours (EMPRASS study) RMH
ESPRIT ESP1/SARC025 Global Collaboration: A phase I study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma. Phase I UCLH CRF ≥ 13 years
ENVASARC A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy. Phase II RMH ≥ 12 years
FaR RMS An overarching study for children and adults with frontline and relapsed rhabdomyosarcoma UCLH >12 months, ≤40 years
GIST Biobank Biobank for GIST RMH
GSK 7011618 SCOOP Phase I Niraparib and Dostarlimab in paediatric patients with recurrent or refractory solid tumours Phase I ULCH <18 years
ICONIC Improving outcomes through collaboration in osteosarcoma UCLH
INBRX-109 (ChonDRAgon) A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma Phase II RMH >_18 years
JV02 A Randomized, Open-Label Phase II Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma Phase III UCLH 12 months to ≤29 years
KINDRED The International Sarcoma Kindred Study: a global multi‐site prospective cancer genetics study. Translational RMH
≥15 years
KX-ORAX-012 An Open-label, Crossover Study of the Effect of Food on the Phannacokinetics of Paclitaxel Administered Orally as Oraxol RMH
OligoRARE (EORTC 1945) Stereotactic body radiotherapy in addition to standard of care treatment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial RMH
ONTRK ON-TRK: PrOspective Noninterventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib RMH
PANTHR-S Precision medicine approaches for neoadjuvant therapy in high‐risk sarcoma patients (PANTHR-S) RMH
PREDICT B Predicting radiotherapy response, toxicities and quality of life related functional outcome in soft tissue sarcoma of the extremities: a prospective observational cohort study RMH,
≥16 years
PROSPECTUS PROgnoStic and PrEdiCTive ImmUnoprofiling of Sarcomas (PROSPECTUS) Retrospective TR study RMH
PTC596-ONC-008-LMS A Phase II/III Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma Phase II/III RMH
Radiomics in Liposarcoma Radiomics In Liposarcoma RMH
rEECur International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory ewing sarcoma. Phase II/III RMH
>4 years and < 50 years
RINGSIDE A Phase II/III, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors Phase II/III RMH
RT Immune A European, Multicentre, Randomized, Open-label, Phase II Trial, aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localised soft tissue sarcomas patients to be treated with radiotherapy. Phase II RMH
SSG XXII A phase III prospective, multi-centre, open-label, 2 arm study for evaluation of 2 durations of adjuvant treatment with the tyrosine kinase inhibitor imastinib mesylate of operable gastrointestinal stromal cells tumour (GIST) with a high risk for recurrence. Phase III UCLH ≥18 years
SMPaeds Stratified medicine paediatrics: genomic characterisation of relapsed paediatric cancers for diagnostics and stratified therapy UCLH Paediatric tumours only
SPEARHEAD 1 A phase II single arm open-label clinical trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Phase II UCLH ≥16 and <75 years
TDM Evaluation of the value of therapeutic drug monitoring to predict treatment outcome in terms of survival and toxicity in patients with solid tumors treated with imatinib, sunitinib and pazopanib RMH